Mr Carey, a sustainable tourism consultant, is heading to the House of Commons on February 26 and to the Scottish Parliament on June 11 in support of UK cholangiocarcinoma charity AMMF’s Rethink Liver ...

Introduction: The care for patients with hepatocellular carcinoma (HCC ... serum alpha-fetoprotein (AFP), abdominal ultrasonography, and CT or MRI scan. The primary endpoint for this study was ...

Objective To characterise gut microbiome in patients with hepatocellular carcinoma (HCC ... Participants’ demographics, clinicopathological data, CT scan, histopathology images and diet habit were ...

Objective Serum α-fetoprotein (AFP) is the most commonly used biomarker for screening hepatocellular carcinoma (HCC) but fails to detect about half of the patients. Thus, we investigated if ...

E-mail: [email protected] Cancer Immunol Res 2025;13:162–70 Current address for T. Kobayashi: Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

We provide the first extensive analysis of RNA editing in the human liver cancer transcriptome. HCC, distinct from most cancer types, is neither a hypo- nor a hyper-editing cancer; instead, HCC ...

A VISION-like, Single-Center Analysis Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans ... in prostate cancer 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts ...

"This process is like a cosmic CT scan, where we can look through different slices of cosmic history and track how matter clumped together at different epochs." A powerful combination of data from ...

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...

Mechanistically, the authors show that inhibiting PLEC results in a disorganized cytoskeleton, deficiency in cell migration, and changes in cancer-relevant signaling pathways. This study demonstrates ...

The median progression-free survival per RECICL was 10.8 months in the combination arm and 3.2 months in the TACE-alone arm. Adding camrelizumab and rivoceranib to transarterial chemoembolization ...

1Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom. 2Department of Translational Medicine (DIMET), University of Piemonte ...